Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Regeneron provides update on Phase III NSCLC trials of Libtayo

NSCLC
Micrograph showing a non-small cell lung carcinoma. Credit: Librepath.